Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells

Journal of Cellular Biochemistry

Volumn 94, Issue 2, 2005, Pages 336-350

  Zhu, Bing ^a   Vemavarapu, Lakshmi ^a   Thompson, W Joseph ^a   Strada, Samuel J ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense; Apoptosis; cGMP; Growth inhibition; HT29; p21 WAF1 CIP1; Phosphodiesterase

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE 5; CYCLIN DEPENDENT KINASE INHIBITOR 1; KT 5720; KT 5823; MESSENGER RNA; PHOSPHODIESTERASE 5A1; PHOSPHODIESTERASE V; SULINDAC SULFONE; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; INDOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL STRAIN HT29; COLON CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOSIS; MOLECULAR CLONING; PLASMID; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL DIVISION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CARBAZOLES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; COLONIC NEOPLASMS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, ANTISENSE; G2 PHASE; HT29 CELLS; HUMANS; INDOLES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 18444366205     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20286     Document Type: Article

References (47)

1. 2 arrest after DNA damage. Science 282:1497-1501.
2. Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA, Jr. 2002. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic tumors. Clin Cancer Res 8:904-912.
3. Davies G, Jiang WG, Mason MD. 2001. The interaction between β-catenin, GSK3β, and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer. Int J Oncol 18:843-847.
4. Davis PK, Ho A, Dowdy SF. 2001. Biological methods for cell-cycle synchronization of mammalian cells. BioTechniques 30:1322-1331.
5. Dietrich C, Wallenfang K, Oesch F, Wieser R. 1997. Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts. Oncogene 15:2743-2747.
6. Dy GK, Adjei AA. 2002. Novel targets for lung cancer therapy: Part II. J Clin Oncol 20:3016-3028.
7. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M. 1998. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 95:3122-3127.
8. Epstein PM. 1998. Antisense inhibition of phosphodiesterase expression. Methods 14:21-33.
9. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC. 2000. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97:3702-3707.
10. Francis SH, Turko IV, Corbin JD. 2000. Cyclic nucleotide phosphodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
11. WAF1/CIP1 expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k). J Biol Chem 275:11389-11396.
12. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. 1998. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 53: 467-474.
13. Ham YM, Choi JS, Chun KH, Joo SH, Lee SK. 2003. The c-Jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis. J Biol Chem 278:50330-50337.
14. Hochedlinger K, Wagner EF, Sabapathy K. 2002. Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene 21:2441-2445.
15. Hsi LC, Angerman-Stewart J, Eling TE. 1999. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 20:2045-2049.
16. Jiang X, Li J, Paskind M, Epstein PM. 1996. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA 93:11236-11241.
17. WAF1/CIF1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells. J Biol Chem 273:30256-30263.
18. Kim SG, Kim SN, Jong HS, Kim NK, Hong SH, Kim SJ, Bang YJ. 2001. Caspase-mediated Cdk2 activation is critical step to execute transforming growth factor-β1-induced apoptosis in human gastric cancer cells. Oncogene 20:1254-1265.
19. Kusama K, Jiang Y, Toguchi M, Ohno J, Shikata H, Sakashita H, Sakagami H. 2000. Use of the monoclonal antibody M30 for detecting HSG cell apoptosis. Anticancer Res 20:151-154.
20. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B. 1999. Immunocytochemical detection and mapping of a cytokeratin 18 neoepitope exposed during early apoptosis. J Pathol 187: 567-572.
21. Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, Sperl GJ, Pamukcu R, Thompson WJ. 2002. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64:1325-1336.
22. Lin CS, Lau A, Tu R, Lue TF. 2000a. Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Biochem Biophys Res Commun 268:596-602.
23. Lin CS, Lau A, Tu R, Lue TF. 2000b. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 268:628-635.
24. Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ. 2002. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal 14:45-51.
25. MacKenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, Houslay MD. 1998. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc Natl Acad Sci USA 95:3549-3554.
26. 2-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 62:5711-5719.
27. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. 1997. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275:1787-1790.
28. Piazza GA, Xu S, Klein-Szanto AJ, Ahnen DJ, Li H, Liu L, David M, Pamukcu R, Thompson WJ. 2000. Overexpression of cGMP phosphodiesterase (cG PDE) in colonic neoplasias compare to normal mucosa. Gastroenterology 118:1590.
29. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE, Jr., Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ. 2001. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 61:3961-3968.
30. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. 2001. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA 98:7846-7851.
31. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE. 2002. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90: 151-157.
32. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J, Merle-Beral H. 2003. Sildenafil and vardenafil, type 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101:265-269.
33. Kip1 in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol 60:900-906.
34. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18:1663-1676.
35. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR. 2000. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 60:5151-5157.
36. Soderling SH, Beavo JA. 2000. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
37. Soh J-W, Mao Y, Kim M-G, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB. 2000. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase. Clin Cancer Res 6:4136-4141.
38. Soh J-W, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. 2001. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem 276:16406-16410.
39. Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. 2002. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res 8:3100-3104.
40. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ. 1979. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10:69-92.
41. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R. 2000. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 60: 3338-3342.
42. Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, Strada SJ. 2002. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol 63:797-807.
43. Tobey RA, Valdez JG, Crissman HA. 1988. Synchronization of human diploid fibroblasts at multiple stages of the cell cycle. Exp Cell Res 179:400-416.
44. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA, Thompson WJ. 2003. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2:479-488.
45. Wu CF, Bishopric NH, Pratt RE. 1997. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Bio Chem 272:14860-14866.
46. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
47. Yoon J-T, Palazzo AF, Xiao D, Delohery TM, Warburton PE, Bruce JN, Thompson WJ, Sperl G, Whitehead C, Fetter J, Pamukcu R, Gundersen GG, Weinstein IB. 2002. CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol Cancer Ther 1:393-404.